DDIT3 and diffuse large B-cell lymphoma: In parallel to the clinical observations, the cell viability of CDCA2-KO cells was equally affected by CHOP and B-CHOP treatment in accordance with the lack of difference in outcome between the two treatment arms for DLBCL patients with low CDCA2 expressions.